Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

Publication Type:

Journal Article


The New England journal of medicine, Volume 369, Issue 18, p.1681-90 (2013)


2013, Adult, Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, November 2013, Prednisone, Public Health Sciences Division, Stem Cell Transplantation, Survival Rate, Transplantation, Autologous, Vincristine


The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the International Prognostic Index remains controversial and is untested in the rituximab era.